Try our beta test site
2 studies found for:    Lymphoma OR CLL | RP6530
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Conditions: Lymphoma, T-Cell, Peripheral;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: RP6530
2 Completed Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
Conditions: Lymphoma, B-Cell;   T-Cell Lymphoma
Intervention: Drug: RP6530

Study has passed its completion date and status has not been verified in more than two years.